Parvovirus B19 (B19V) is a human pathogen belonging to the Parvoviridae family. It is widely diffused in the population and responsible for a wide range of diseases, diverse in pathogenetic mechanisms, clinical course, and severity. B19V infects and replicates in erythroid progenitor cells (EPCs) in the bone marrow leading to their apoptosis. Moreover, it can also infect, in an abortive manner, a wide set of different cell types, normally non-permissive, and modify their normal physiology. Differences in the characteristics of virus–cell interaction may translate into different pathogenetic mechanisms and clinical outcomes. Joint involvement is a typical manifestation of B19V infection in adults. Moreover, several reports suggest, that B19V could be involved in the pathogenesis of some autoimmune rheumatologic diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), or vasculitis. This review provides basic information on the B19 virus, highlights characteristics of viral infection in permissive and non-permissive systems, and focuses on recent findings concerning the pathogenic role of B19V in rheumatologic diseases.

Background. Understanding the interference patterns of respiratory viruses could be important for shedding light on potential strategies to combat these human infectious agents. Objective. To investigate the possible interactions between adenovirus type 2 (AdV2), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A/H1N1 pandemic (H1N1pdm09) using the A549 cell line. Methods. Single infections, co-infections, and superinfections (at 3 and 24 h after the first virus infection) were performed by varying the multiplicity of infection (MOI). Virus replication kinetics and the mRNA expression of IFN-α, IL-1α and IL-6 were assessed by real-time qPCR. Results. Co-infection experiments showed different growth dynamics, depending on the presence of the specific virus and time. AdV2 replication remained stable or possibly enhanced in the presence of co-infection with each of the two H1N1pdm09 and SARS-CoV-2 viruses used. In contrast, SARS-CoV-2 replication was facilitated by H1N1pdm09 but hindered by AdV2, indicating possible different interactions. Finally, H1N1pdm09 replication exhibited variably effectiveness in the presence of AdV2 and SARS-CoV-2. Superinfection experiments showed that the replication of all viruses was affected by time and MOI. The mRNA expression of IFN-α, IL-1α and IL-6 showed divergent results depending on the virus used and the time of infection. Conclusions. Further investigation of co-infection or superinfection may be helpful in understanding the potential relationship involved in the outcome of viral respiratory infection in the human population.

Merkel cell polyomavirus (MCPyV) is associated with Merkel cell carcinoma (MCC). In tumor cells the MCPyV large T antigen (LT-Ag) is frequently found truncated and this is considered a major tumor-specific signature. The role of MCPyV in other, non-MCC tumours, is little known. Viral DNA and/or tumour-specific mutations have been sometimes detected in different tumours, but such data are not unequivocal and the involvement of the virus in the tumorigenesis is not clear. In a previous study, we demonstrated a significantly higher prevalence of MCPyV DNA in formalin fixed paraffin embedded (FFPE) porocarcinoma tissues compared to the normal skin. In the present study, we investigated the presence of truncating mutations in MCPyV LT-Ag coding region in porocarcinoma specimens. Using several overlapped PCR primer pairs, the complete LT-Ag sequence from two biopsies were obtained. No truncating mutations were detected. The lack of truncating mutations in LT-Ag sequence does not seem to support the role of MCPyV in porocarcinoma oncogenesis. However, an oncogenetic mechanism, different from that proposed for MCC and not associated with the LT-Ag mutations/deletions, cannot be excluded. Further studies of more sequences coding for LT-Ag would be needed to verify this hypothesis.

The mechanisms underlying post-acute sequelae of SARS-CoV-2 infection (PASC) are a topic of debate. This study examined the presence of SARS-CoV-2 microRNA (miRNA)-like small RNAs in extracellular fluids and their potential link to PASC by using a quantitative stem-loop RT-PCR MiRNA assay. Initially, it was demonstrated that three previously identified SARS-CoV-2 miRNA-like small RNAs, specifically svRNA 1 and 2 and miR-07a, were significantly expressed in infected cells in vitro and released into the supernatant following infection by different SARS-CoV-2 variants. Then, the expression of three SARS-CoV-2 small RNAs was studied in both nasopharyngeal swabs (NPS) and sera from 24 patients at their initial COVID-19 diagnosis (T0) and in sera collected 91 to 193 days post-diagnosis (T1). Notably, 11 out of 24 patients (46%) reported PASC consequences. All NPS samples showed SARS-CoV-2 small RNA expression with an altered cytokine network during acute infection, but it did not correlate with PASC outcomes. Serum samples had similar small RNA statuses, though PASC patients, notably at T1, but not at T0, displayed reduced overall positivity compared to those without PASC. The host target expression of SARS-CoV-2 small RNAs was not significantly different between groups. This suggests a need for further research into SARS-CoV-2 small RNA and its role in viral behavior and PASC consequences.

Background: Influenza virus isolation in cell cultures can be a foremost activity in the surveillance of the epidemiological characteristics involved in the vaccination strategies. Methods and results: Here, the virus isolation effectiveness from double positive throat swab to influenza A virus (H1N1pdm09 or H3N2) and SARS-CoV-2 compared to those obtained from single positive throat swab samples was investigated by serial passages of throat swabs samples in cell cultures. Viral replication and IFN-α, IL-1α, and IL-6 cytokine expression at three passages were measured by RT-PCR amplification. Virus isolation using a throat swab samples resulted double positive to influenza A virus (H1N1pdm09 or H3N2) and SARS-CoV-2 showed a different effectiveness compared to a throat samples single positive to each of these viruses. The virus isolation efficacy was independent from an active replication of the two viruses in the inoculum and showed a virus strain-specific reduction in cytokines profile compared to a single infection. Conclusion: Collectively the results point out to take into account the presence of co-circulating respiratory viruses in human samples for virus isolation effectiveness.

Background: SARS-CoV-2 fusion inhibitory peptides represent promising antiviral candidates. Recently, a 19-mer peptide (PN19)—designed in our laboratory to mimic the internal fusion peptide of the SARS-CoV-2 spike S2 subunit—demonstrated potent antiviral activity and stable conformational features. Objectives: To investigate how this antiviral activity depends on membrane interactions, we designed synthetic PN19 lipopeptide derivatives and evaluated their efficacy against SARS-CoV-2 replication. Methods: Lipopeptides were synthesized by conjugating cholesterol to either the N- or C-terminus of the PN19 peptide, utilizing a Gly/Ser pentapeptide (GSGSG) and/or various polyethylene glycol (PEG) spacers. Antiviral activity against SARS-CoV-2 variants was evaluated by plaque reduction assays, and cytotoxicity was assessed in Vero E6 cells. Results: The lipopeptides exhibited potent inhibitory activity at sub-micromolar concentrations. Compared to the unmodified PN19 peptide, antiviral efficacy was significantly enhanced by cholesterol conjugation at either terminus. Evaluation of six PN19 lipopeptides bearing the GSGSG sequence and different PEG spacers revealed that C-terminal cholesterol conjugation yielded higher antiviral activity than N-terminal derivatives. Furthermore, thirteen shorter PN19 lipopeptide derivatives (8–13-mers) confirmed this robust efficacy, which was most pronounced with C-terminal cholesterol conjugation and further enhanced by the spacers. Noteworthy, all tested PN19 lipopeptides displayed broad activity against multiple SARS-CoV-2 variants in the absence of cytotoxicity. Conclusions: Collectively, peptides conjugated with cholesterol at the C-terminus emerged as highly potent inhibitors of SARS-CoV-2, likely driven by enhanced peptide–membrane interactions. These findings warrant further investigation to fully elucidate the role of lipidation in the inhibitory mechanism, supporting the development of novel antiviral lipopeptides for SARS-CoV-2 therapy.